These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 12080274)

  • 21. Efficacy and safety of 3 mg drospirenone/20 mcg ethinylestradiol oral contraceptive administered in 24/4 regimen in the treatment of acne vulgaris: a randomized, double-blind, placebo-controlled trial.
    Koltun W; Lucky AW; Thiboutot D; Niknian M; Sampson-Landers C; Korner P; Marr J
    Contraception; 2008 Apr; 77(4):249-56. PubMed ID: 18342647
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An oral contraceptive with 3 approved indications.
    Mishell DR
    J Reprod Med; 2008 Sep; 53(9 Suppl):717-9. PubMed ID: 18980043
    [No Abstract]   [Full Text] [Related]  

  • 23. Evolution of progestins. Focus on the novel progestin drospirenone.
    Thorneycroft IH
    J Reprod Med; 2002 Nov; 47(11 Suppl):975-80. PubMed ID: 12497671
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Added benefits of drospirenone for compliance.
    Foidart JM
    Climacteric; 2005 Oct; 8 Suppl 3():28-34. PubMed ID: 16203653
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and tolerance of acne treatment using both spironolactone and a combined contraceptive containing drospirenone.
    Krunic A; Ciurea A; Scheman A
    J Am Acad Dermatol; 2008 Jan; 58(1):60-2. PubMed ID: 17964689
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Choosing the appropriate oral contraceptive.
    Langer A; Devanesan M; Pelosi MA
    Drug Ther (NY); 1978 Jun; 8(7):112-20. PubMed ID: 12260696
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Use of an oral contraceptive containing drospirenone in an extended regimen.
    Sillem M; Schneidereit R; Heithecker R; Mueck AO
    Eur J Contracept Reprod Health Care; 2003 Sep; 8(3):162-9. PubMed ID: 14667328
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Yasmin advert withdrawn--why and how.
    Drug Ther Bull; 2003 Mar; 41(3):17-8. PubMed ID: 12683099
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ethinyl estradiol/drospirenone (Yasmin): a newer oral contraceptive.
    Somma MA
    Am Fam Physician; 2004 May; 69(10):2425-6. PubMed ID: 15168965
    [No Abstract]   [Full Text] [Related]  

  • 30. Higher risk of venous thrombosis associated with drospirenone-containing oral contraceptives: a population-based cohort study.
    Gronich N; Lavi I; Rennert G
    CMAJ; 2011 Dec; 183(18):E1319-25. PubMed ID: 22065352
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Contraception and the dermatologist.
    Tyler KH; Zirwas MJ
    J Am Acad Dermatol; 2013 Jun; 68(6):1022-9. PubMed ID: 23332517
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Yasmin--a new oral contraceptive, a new progestogen: the reasons why.
    Mansour D
    Eur J Contracept Reprod Health Care; 2000 Dec; 5 Suppl 3():9-16. PubMed ID: 11246601
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy, acceptability and tolerability of the combined contraceptive ring, NuvaRing, compared with an oral contraceptive containing 30 microg of ethinyl estradiol and 3 mg of drospirenone.
    Ahrendt HJ; Nisand I; Bastianelli C; Gómez MA; Gemzell-Danielsson K; Urdl W; Karskov B; Oeyen L; Bitzer J; Page G; Milsom I
    Contraception; 2006 Dec; 74(6):451-7. PubMed ID: 17157101
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of a low-dose 24-day combined oral contraceptive containing 20 micrograms ethinylestradiol and 3 mg drospirenone.
    Bachmann G; Sulak PJ; Sampson-Landers C; Benda N; Marr J
    Contraception; 2004 Sep; 70(3):191-8. PubMed ID: 15325887
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Yasmin and venous thromboembolism: new case reports.
    López M; Vayá A; Martínez Triguero ML; Contreras MT; Todolí J; Ricart A; Laiz B
    Clin Hemorheol Microcirc; 2009; 42(1):65-9. PubMed ID: 19363241
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of a combination of ethinylestradiol 30 microg and drospirenone 3 mg on tolerance, cycle control, general well-being and fluid-related symptoms in women with premenstrual disorders requesting contraception.
    Borges LE; Andrade RP; Aldrighi JM; Guazelli C; Yazlle ME; Isaia CF; Petracco A; Peixoto FC; Camargos AF
    Contraception; 2006 Dec; 74(6):446-50. PubMed ID: 17157100
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacology of different progestogens: the special case of drospirenone.
    Sitruk-Ware R
    Climacteric; 2005 Oct; 8 Suppl 3():4-12. PubMed ID: 16203650
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Serum potassium monitoring for users of ethinyl estradiol/drospirenone taking medications predisposing to hyperkalemia: physician compliance and survey of knowledge and attitudes.
    Mona Eng P; Seeger JD; Loughlin J; Oh K; Walker AM
    Contraception; 2007 Feb; 75(2):101-7. PubMed ID: 17241838
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Advances in the treatment of acne.
    Kimball AB
    J Reprod Med; 2008 Sep; 53(9 Suppl):742-52. PubMed ID: 18980046
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Thirty years after the appearance of the first oral contraceptive, clinical and biological analysis of a new estrogen-progestin combination, a three phase pill containing gestodene].
    Belaisch J; Hommais-loufrani B
    Fertil Contracept Sex; 1988 Apr; 16(4 Suppl):1-8. PubMed ID: 12342078
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.